Introduction
Organ transplant recipients receive lifelong immunosuppression and are at risk of morbidity and mortality from influenza infection. Although influenza vaccine is recommended annually for this group, it has suboptimal immunogenicity (1) . Vaccine immunogenicity in the transplant setting is dependent on multiple factors including time from transplantation, use of specific immunosuppressive agents (e.g. mycophenolate mofetil [MMF] ) and type of transplant (1) (2) (3) . Use of a vaccine adjuvant may also increase immunogenicity after transplant in certain subpopulations (4) .
Vaccine immunogenicity is typically evaluated by measuring strain-specific (i.e. homologous) rates of seroconversion and seroprotection. Nevertheless, evidence from the general population shows that influenza vaccines can also induce heterologous immune responses, namely, seroconversion or seroprotection to influenza strains not included in the vaccine (5) . Demonstration of heterologous immune responses would provide further impetus to increase vaccine uptake in transplant patients. The mechanism for heterologous immune response may be based on sequence similarity of heterologous versus homologous strains or may be secondary to antibodies directed against conserved regions. These responses would be especially important during seasons of antigenic drift in which vaccine strains are not a perfect match with circulating strains. In addition, it has been shown that adjuvanted vaccines induce broader heterologous responses (6) (7) (8) in immunocompetent people. Adjuvanted influenza vaccines may be more immunogenic overall, with the effect of adjuvants mediated through Toll-like receptors or by inducing local inflammatory effects. In a randomized trial of adjuvanted versus nonadjuvanted influenza vaccine in children aged 6 mo to 6 years, adjuvanted vaccine was able to elicit a greater response than nonadjuvanted vaccine to strains not included in either vaccine (9) . Similarly, a heterologous response was more commonly seen when adjuvanted vaccine was compared with conventional vaccine in those aged >65 years (10).
Currently there are no studies evaluating heterologous immune response to influenza vaccine (either nonadjuvanted or adjuvanted) in transplant patients. The purpose of this study was to determine whether influenza vaccine in transplant patients could induce heterologous antibody responses against strains not included in the vaccine. We used samples collected during the randomized trial to assess heterologous immune response to a spectrum of strains that ranged from closely related to only moderately related to the vaccine strain. We also evaluated whether adjuvanted vaccine was associated with a higher likelihood of a heterologous response.
Methods
We used serum samples obtained during a previous randomized trial of nonadjuvanted versus adjuvanted vaccine after kidney transplant (4) . Briefly, during the 2012-2013 influenza vaccination campaign, kidney transplant patients were randomized 1:1 to receive either the MF59 adjuvanted vaccine (Fluad; Novartis, Basel, Switzerland) or the nonadjuvanted vaccine (Agriflu; Novartis). Both vaccines contained the same amount (15 lg) of antigen from three influenza strains in 0. Serum samples were stored at À80°C until used, and 60 patients' paired samples were available of the original 68 patients enrolled in the study. Testing for vaccine-specific strains (homologous immunity) was done as part of the prior study. For the current study, stored samples were used to perform hemagglutination inhibition assay to the following heterologous influenza strains: A/New Caledonia/20/99 (H1N1), A/Texas/50/2012 (H3N2) and B/Brisbane/60/2008 (Victoria lineage) (11) . Sequence homology between the hemagglutinin (HA) gene segments of the heterologous strains with their corresponding vaccine strains was determined using FASTA sequences available through the National Center for Biotechnology Information (NCBI) and alignment tools on BLAST (NCBI, Bethesda, MD). Using this method, there was 78% sequence homology for HA between the H1N1 strains, 99% between the H3N2 strains and 90% between the B strains. These three strains were chosen for assessing heterologous responses because they represented a spectrum of moderate to high sequence homology. In addition, testing heterologous titers to A/New Caledonia/20/99 (H1N1) would provide information on recall responses because this strain was in circulation and was included in the vaccine from 2000 to 2007. Titers to A/Texas/50/2012 (H3N2) would allow us to determine response to a novel strain that was newly introduced after the trial was complete. In addition, titers to B/Brisbane/60/ 2008 (Victoria lineage) would allow us to determine cross-lineage responses.
The hemagglutination inhibition assay was performed at the Virus Reference Department, Public Health England, Colindale, United Kingdom, using methods described previously (12) . Briefly, serum was incubated with receptor-destroying enzyme (RDE II; Denka Seiken Co., Ltd., Tokyo, Japan) to remove any nonspecific inhibitors of hemagglutination from the sera. Sera were serially diluted and incubated with influenza virus (containing four hemagglutination units of virus). This was followed by addition of a suspension of blood cells (0.5% turkey red blood cells for the H1N1 and B strains and 0.5% guinea pig red blood cells for the H3N2 strain). Titers were determined by doubling dilutions of antibody. Sera were tested in duplicate using an initial dilution of 1:10 and a final dilution of 1:2048. Antibody concentrations that were below the lower limit of detection (<10) were assigned a titer of 5 for the purposes of analysis.
Definitions and statistics
Vaccine immunogenicity was assessed using the World Health Organization-recommended definitions: Seroprotection to a strain was defined as a strain-specific postvaccination titer ≥1:40. Seroconversion was defined as a fourfold or greater rise in titer from baseline. Seroconversion factor was derived by dividing the postimmunization titer by the prevaccine titer. Geometric mean fold rise was calculated as the geometric mean of seroconversion factor. Demographics were analyzed using descriptive statistics. Associations between heterologous and homologous humoral immunity and statistical analysis was performed using IBM SPSS version 22.0 (IBM Corp, Armonk, NY) and GraphPad Prism version 4.0 (GraphPad Software, La Jolla, CA).
Results

Patient cohort
A total of 60 paired samples (before and after influenza vaccination) were available for heterologous strain testing. All participants were kidney or kidney-pancreas transplant recipients and were a median of 7.6 years from transplant. The majority were on triple immunosuppression including prednisone, calcineurin inhibitor and mycophenolate. This is a subset of patients from the previous clinical trial, and the demographics of the full cohort were published previously (4) . Of the 60 patients, 31 (52%) had received adjuvanted influenza vaccine and 29 (48%) had received nonadjuvanted vaccine ( Table 1) . The seroconversion responses to homologous (i.e. vaccine) strains were 46.7%, 41.7%, and 28.3% for A/ H1N1, A/H3N2 and B strains, respectively. There were no significant differences in homologous strain immunity between the adjuvanted and nonadjuvanted vaccines (4).
Response to heterologous strains Seroconversion to heterologous strains was seen in 16.7%, 41.7%, and 13.3% of A/H1N1, A/H3N2, and B strains, respectively (Table 2) . Similarly, heterologous seroprotection rates after vaccination reached 88.3%, 78.3%, and 38.3% for A/H1N1, A/H3N2, and B strains, respectively. Patients had relatively high baseline (prevaccination) seroprotective titers to heterologous A/H1N1 (78.3%) and lower titers for A/H3N2 (48.3%) and B (25.0%).
No significant differences were seen between the adjuvanted and nonadjuvanted vaccines with regard to vaccine immunogenicity to heterologous strains. Heterologous seroconversion rates, for example, ranged from 9.7% to 41.9% for the adjuvanted vaccine and from 10.3% to 41.4% for the nonadjuvanted vaccine (p-value not significant for all comparisons). Heterologous seroprotection rates were generally higher and ranged from 41.9% to 90.3% for adjuvanted vaccine and from 34.5% to 86.2% for nonadjuvanted vaccine (p-value not significant for all comparisons).
No factors were significantly predictive of heterologous strain response (Table 3) . Factors analyzed included age, time from transplant, and use of immunosuppression (MMF use and dose, tacrolimus and cyclosporine levels).
Comparison of heterologous and homologous immune responses
Because there were no significant differences in heterologous immunity between adjuvant and standard vaccines, we compared homologous and heterologous strain immunity in the total cohort of 60 patients. Significant differences were seen in heterologous and homologous immune responses, with overall lower responses for heterologous strains (Table 4) . Seroprotection rates to A/ H3N2, for example, were lower in the heterologous strain (78.3% vs. 96.7%; p = 0.001). Similarly, seroconversion rate to A/H1N1 was lower for the heterologous strain (16.7% vs. 46.7%; p < 0.001). Prevaccination geometric mean titers (GMTs) for heterologous A/H1N1 were significantly greater than prevaccination GMTs for the homologous H1N1 strain (80.9 vs. 30.0; p = 0.005); however, postvaccination GMTs were similar to that of the homologous strain. For heterologous A/H3N2 and B, GMTs were significantly lower than those of the homologous strains (p < 0.001 for both A/H3N2 and B). Heterologous response to a specific strain was more likely if a patient had seroconverted to the homologous strain ( Figure 1 ). Heterologous seroconversion, for example, was present in 84.0% of patients who seroconverted to vaccine strain H3N2 compared with 11.4% of patients that did not seroconvert (p < 0.001); however, heterologous responses across HA types were generally not observed. 
Discussion
The development of heterologous immunity to vaccines has not been evaluated previously in immunosuppressed transplant recipients. Our study is the first to show that kidney transplant recipients were capable of mounting cross-protective humoral responses to heterologous influenza strains. We observed a significant rise in absolute titer after vaccination with all heterologous strains used in this study. This result provides important evidence in support of vaccination even if response rates may be suboptimal or if there is a mismatch between vaccine strains and currently circulating strains. Based on our results in a subset of patients, protection from vaccination extends to strains that are not present in the vaccine, even when moderate heterogeneity in HA sequence is observed. We also observed that seroconversion to a heterologous strain was correlated with seroconversion to the vaccine strain. Overall, however, the absolute rate of seroconversion to a heterologous strain was lower than to the corresponding vaccine strains. Those who received adjuvanted vaccine had similar heterologous immunogenicity compared with recipients of nonadjuvanted vaccine.
Heterologous immunity to influenza infection and vaccination has been studied previously in animal models and immunocompetent persons. In general, HA antibodies induced by vaccination are strain-specific, and their cross-reactivity to other strains is limited. More recently, however, Corti et al found that seasonal influenza vaccination in some persons can induce protective antibodies that cross-react with other HA types such as H5 HA (13) . During natural influenza infection, broadly cross-reactive antibodies that bind to the HA stem are formed. The stem region of HA is required for membrane fusion and is highly conserved; therefore, cross-reactive antibodies are directed against epitopes that are conserved between strains. Iorio et al demonstrated that cellular immune responses (as determined by interferon-c production) against a heterologous H1N1 strain could be boosted by vaccination in a cohort of 17 healthy adult participants (14) . In that study, peripheral blood mononuclear cells were stimulated with an HA peptide corresponding to the amino acid sequences present in a functionally conserved region of the protein.
In our study, we evaluated cross-reactive influenza responses formed by vaccination to strains with HA sequences that were either relatively different (A/New Caledonia/20/99 [H1N1]) or relatively similar (A/Texas/50/ 2012 [H3N2]). Because the majority of our patients were vaccinated in previous seasons, through measurement of A/New Caledonia (H1N1), we also evaluated whether patients would have recall responses to heterologous strains. This strain was in circulation and included in the North American influenza vaccine from 2000 to 2007 (http://www.fludb.org). We found that GMTs to heterologous H1N1 increased significantly after vaccination, suggesting significant cross-protection provided by vaccination and possible recall of prior vaccination or infection. Nevertheless, the seroconversion rate and seroconversion factor to heterologous H1N1 was significantly lower than the corresponding homologous H1N1 strain. This may be a result of the large variation in their HA sequences or a high prevaccination titer.
In contrast, prevaccination immunity to heterologous H3N2 was lacking in the cohort. This was expected because the heterologous strain had not significantly circulated in prior seasons and was a newly introduced strain in the 2013-2014 vaccine (i.e. after the samples were collected for the study). After vaccination, GMTs significantly increased to heterologous H3N2, and seroconversion rates were similar to seroconversion rates of the homologous strain (41.7%). This result suggests that responses in immunosuppressed persons may be retained to novel or drift variants of influenza viruses. This may also be a function of high HA sequence homology (99%) between the vaccine H3N2 strain and the heterologous H3N2 strain. Cross-lineage responses for the B strain were low, with seroconversion ranging from 10% to 16%.
We found no differences in heterologous immunity between adjuvanted and nonadjuvanted vaccines. Previous literature showed that adjuvanted influenza vaccine may induce broader cross-protective responses than other types of influenza vaccines. Baldo et al showed that GMTs against drifted A strains were higher for subunit MF59 vaccine than a nonadjuvanted vaccine in elderly persons (6). Banzhoff et al showed that MF59-adjuvanted H5N1 vaccine against one clade induced heterologous response to other H5N1 types in healthy adults and children (15, 16) . Our study showed that transplant patients are able to mount heterologous responses, but this did not vary with vaccine type, potentially because of immunosuppression that targets cells that are also recruited by the MF59 adjuvant.
A potential downside of heterologous immune responses to vaccination is the development of antibodies directed against the allograft. Some studies have suggested that influenza vaccine may increase the risk of allograft rejection, as was highlighted during the 2009 influenza pandemic, specifically using the ASO3-adjuvanted monovalent pandemic vaccine (17, 18) . A significant proportion of organ rejection is mediated by HLA alloantibodies, and a proposed mechanism by which influenza vaccine could lead to rejection is via heterologous immune responses, namely, formation of nonspecific antibodies against HLA antigens that are induced by a vaccine-associated inflammatory response. We and other groups have systematically investigated the development of HLA alloantibodies after seasonal influenza vaccination and found no significant increases in de novo donorspecific HLA antibody after vaccine (2, 19, 20) .
Our study has some limitations. We did not evaluate cross-protective responses to pandemic strains that have undergone significant reassortment or mutation. In addition, most patients have been vaccinated previously and have high baseline antibody titers to heterologous strains (e.g. A/H3N2). This may reflect the cross-protective nature of prior vaccination, and the results may not be applicable to those who do not receive annual vaccination. Finally, we did not perform a direct comparison of our results to immunocompetent adults, and this would be important in future studies.
In summary, this study is the first to demonstrate that influenza vaccine may have the additional benefit of inducing heterologous antibody production directed against nonvaccine strains of influenza in an immunosuppressed population. This study provides a further rationale for recommending yearly influenza vaccine to this highly susceptible population.
